Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). (Q34618193)

3 August 2017

1 reference

title

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). (English)

1 reference

3 August 2017

0 references

1 reference

2

Greg L Plosker

1 reference

3 August 2017

Risto S Cvetković

1

1 reference

3 August 2017

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

67

1 reference

3 August 2017

6

1 reference

3 August 2017

935-954

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767060-00008

3 August 2017

0 references

cites work

Incretin mimetics as emerging treatments for type 2 diabetes

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767060-00008

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767060-00008

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767060-00008

Therapeutic approaches to preserve islet mass in type 2 diabetes

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

12 December 2020

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

1 reference

12 December 2020

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Effect of exenatide on the steady-state pharmacokinetics of digoxin.

1 reference

12 December 2020

Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

1 reference

12 December 2020

Relationships of upper gastrointestinal motor and sensory function with glycemic control

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.

1 reference

12 December 2020

Investigation of exenatide elimination and its in vivo and in vitro degradation.

1 reference

12 December 2020

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).

1 reference

12 December 2020

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects

1 reference

12 December 2020

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

1 reference

12 December 2020

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

12 December 2020

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

12 December 2020

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

1 reference

12 December 2020

Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.

1 reference

12 December 2020

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

12 December 2020

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

12 December 2020

Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes

1 reference

12 December 2020

Exenatide: a new option for the treatment of type 2 diabetes

1 reference

12 December 2020

Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines

1 reference

12 December 2020

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Diabetes drug update: how 4 new options stack up.

1 reference

12 December 2020

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

12 December 2020

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus

1 reference

12 December 2020

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

1 reference

12 December 2020

Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.

1 reference

12 December 2020

Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4.

1 reference

12 December 2020

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

1 reference

12 December 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

12 December 2020

Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level

1 reference

12 December 2020

Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells

1 reference

12 December 2020

10.2165/00003495-200767060-00008

Identifiers

DOI

1 reference

PubMed ID

17428109

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

17428109